United States: CMS Publishes Physician Payment Sunshine Rules; Manufacturers And Group Purchasing Organizations Are Required to Submit Detailed Annual Reports

On February 1, 2013, the Centers for Medicare and Medicaid Services (CMS) published the long-awaited rules (the "Rules") detailing manufacturers' and group purchasing organizations' reporting requirements under Section 6002 of the Affordable Care Act, otherwise known as the Physician Payment Sunshine Act (the "Act"). The Act generally requires applicable manufacturers and group purchasing organizations (GPOs) to report to CMS physician ownership or investment interests in the applicable manufacturer or GPO. Manufacturers must also report payments or transfers of value that are made to physicians or teaching hospitals. The focus of the Rules is apparent: Payments or transfers of value must be reported, and they must be reported only once. Thus, unique questions are presented for subsidiaries, co-promoters, joint ventures and entities engaged in limited applicable manufacturing. It may be prudent to carefully analyze each such arrangement to ensure that reports are timely made by the proper entity. CMS will eventually make all information reported publicly available online, and the penalties for missing or inaccurate reports are stiff. Therefore, affected entities should consider implementing a plan for collecting, monitoring and reporting all information covered by the Act and the Rules.

What Every Applicable Manufacturer and GPO Should Know

  • Data collection for reporting purposes must begin on August 1, 2013.
  • Records must be maintained for five years.
  • Reports must be submitted to CMS by March 31, 2014.
  • Applicable manufacturers and GPOs must assess all co-promoter, joint venture or collective manufacturing agreements to determine which entity must report under the Act.
  • The following information is subject to reporting by applicable manufacturers:
    • Payments or transfers of value,
    • From applicable manufacturers' or GPOs to physicians and teaching hospitals,
    • In excess of $10, or an annual aggregate in excess of $100; and
  • GPOs and applicable manufacturers must also report ownership or investment interests held by physicians.
  • CMS has the authority to audit, evaluate and inspect an organization for compliance with the Act.
  • Failure to report subjects an applicable manufacturer or GPO to civil monetary penalties (CMPs) of up to $100,000 annually, or $1,000,000 for knowing failures to report.
  • The Act preempts state law reporting requirements.

Who Must Report? Applicable Manufacturers and GPOs

The Act and the Rules impose reporting requirements on two entities: applicable manufacturers and GPOs. Only applicable manufacturers, however, are required to report payments or transfers of value to physicians or teaching hospitals. For manufacturers, the organization has reporting requirements if it is:

  • Engaged in the production, preparation, propagation, compounding or conversion of a covered drug for sale or distribution in the United States, including foreign manufacturers that operate in the United States by selling a product (regardless of where the product is physically manufactured); or
  • Under common ownership with such an entity with respect to such acts.

In situations of common ownership, co-promotion, joint ventures, distributor or wholesaler relationships, or the parent/subsidiary context, the scope of "applicable manufacturer" should be analyzed to ensure that the proper entity submits reports and that each party appropriately insulates itself from the improper reporting of the reporting entity. Applicable manufacturers generally include co-promoters of drugs or devices, but under the new rules, only the entity that actually furnishes the payment or other transfer of value must make a report, unless the parties agree to other reporting arrangements. Also subject to the reporting requirements are wholesalers and distributors (including repackagers, relabelers and kit assemblers) that actually hold title to the covered drug, device, biological or medical supply, as well as entities that hold an FDA approval, license or clearance for a covered product. Because only one entity needs to report covered payments or transfers of value, wholesalers and distributors would need to determine which of the wholesaler, distributor or manufacturer is actually making the payment or transfer of value, and that entity generally must report.

An applicable manufacturer generally does not include: (1) raw materials and component manufacturers; (2) hospitals, pharmacies and laboratories that produce or manufacture materials solely for their own use or use by their patients; or (3) pharmacies / compounding pharmacies that (a) maintain establishments that are compliant with state and local laws, (b) regularly engage in distributing prescription drugs or devices and (c) do not produce, propagate, compound or convert drugs/devices for sale other than in the regular course of their business of selling devices or drugs at retail to individual patients.

GPO, on the other hand, is defined to include GPOs operating in the United States that purchase, arrange for or negotiate the purchase of covered drugs, devices, biologicals or medical supplies. It does not include hospitals or large physician practices that purchase covered drugs, devices, biologicals or medical supplies for their own uses.

While an "applicable manufacturer" and GPO may include a variety of entities in the supply chain, there is a key limitation to both definitions—reporting requirements are limited to applicable manufacturers and GPOs of a covered drug, device, biological or medical supply. CMS has defined this to mean any drug, device, biological or medical supply for which payment is available under Medicare or Medicaid, but it does not include over-the-counter drugs and biologicals or many Class I and Class II devices that are exempt from the premarket notification requirements.

What Must Be Reported?—Payments, Transfers of Value and Certain Ownership and Investment Interests

Payments and Transfers of Value

Although the definitions of an applicable manufacturer and GPO are tied to work related to a "covered drug, device, biological, or medical supply," CMS has said that payments or transfers of value do not need to be related to the covered drug, device, biological or medical supply—all payments or transfers of value to a physician or teaching hospital must be reported, unless the applicable manufacturer derives less than 10 percent of its gross revenue from covered drugs, devices, biologicals or medical supplies.

Payments and transfers of value can include:

  • Cash or a cash equivalent;
  • In-kind items or services;
  • Stock, a stock option or any other ownership interest, dividend, profit or other return on investment;
  • Consulting fees;
  • Compensation for services other than consulting;
  • Honoraria;
  • Gift;
  • Entertainment;
  • Food;
  • Travel;
  • Education;
  • Research;
  • Charitable contribution;
  • Royalties or licenses;
  • Current or prospective ownership or investment interest;
  • Direct compensation for serving as faculty or as a speaker for a medical education program;
  • Grants; and
  • Any other nature of the payment or other transfer of value.

There are several exceptions, including product samples or educational materials that benefit patients or are for patient use, but the largest exception is that payments or transfers of value of less than $10 need not be reported, unless the aggregate annual amount exceeds $100.

Certain Ownership and Investment Interests

GPOs and applicable manufacturers must also report physician ownership and investment interests. Physicians do not need to be employees of the GPO or applicable manufacturer, and the reporting requirements extend to immediate family members of any physician.

The definitions of ownership and investment interests mirror those in the physician self-referral law, commonly referred to as the Stark Law, and include both direct and indirect interests, such as stock; stock options; partnership shares; limited liability company memberships; loans; bonds; and any other interest through debt, equity or other means. Such interests do not include interests arising out of retirement plans, stock options or convertible securities received as compensation, or unsecured loans subordinate to credit facilities.


Penalties for non-compliance with the reporting requirements are substantial. Failure to report may subject applicable manufacturers and GPOs to an annual CMP of at least $10,000, but not more than $100,000. If the failure to report was knowing, CMPs may be imposed up to $1,000,000. These penalties are compounded when an entity submits a consolidated report on behalf of applicable manufacturers under common ownership—the entity submitting the report must attest to the accuracy of a report, and if it is false, the entity submitting the report will be subject to the maximum penalties for each individual manufacturer included in the consolidated report. Thus, robust indemnity provisions appear to be a necessity in co-ownership situations or under reporting agreements.

Whether the maximum penalties will be imposed is left to the discretion of CMS, but factors CMS considers in imposing CMPs include the:

  • Length of time the GPO or applicable manufacturer failed to report;
  • Amount of payment or transfer of value that was not reported;
  • Level of culpability;
  • Nature and amount of information reported in error; and
  • Degree of diligence exercised in correcting the report.

To facilitate the audits and evaluations authorized by the Act, applicable manufacturers and GPOs must maintain their books and records for five years.

State Law Preemption

Finally, the Act preempts state law reporting requirements, which means that applicable manufacturers and GPOs presently reporting the same information under state and local laws will no longer be obligated to do so, and no state or local government may require separate reporting of the information required to be reported under the Act, unless the information is being collected by a federal, state or local governmental agency for public health purposes. Applicable manufacturers and GPOs may want to consider treading carefully, as the Act's preemption has not yet been tested in courts. As a result, it may be worthwhile to carefully analyze any state and local reporting laws against the Act before any applicable manufacturers or GPOs cease reporting under state and local laws.


The Act now imposes hefty reporting requirements that may dramatically increase costs associated with the collection, monitoring and management of information related to payments or transfers of value to covered recipients. As the reporting period commences in less than six months—and the penalties are stiff—it may be prudent to develop appropriate policies and processes now to ensure accurate and compliant information gathering and reporting.

If you have any questions about this Alert or would like more information, please contact Elinor L. Hart, Frederick (Rick) R. Ball, any of the attorneys in our Pharmaceutical, Medical Device, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Strasburger & Price, L.L.P.
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Strasburger & Price, L.L.P.
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions